Insight Molecular Diagnostics Inc. SEC filings IMDX
Insight Molecular Diagnostics Inc. has 688 filings in SEC EDGAR's recent list, going back to May 14, 2015. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 10, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 21, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Apr 30, 2026 | — |
| DEF 14A | Proxy statement | Apr 30, 2026 | Apr 30, 2026 |
| DEFA14A | Additional proxy material | May 14, 2025 | — |
| DEF 14A | Proxy statement | May 14, 2025 | May 14, 2025 |
| DEF 14A | Proxy statement | Sep 25, 2024 | Sep 25, 2024 |
| DEF 14A | Proxy statement | Apr 29, 2024 | Apr 29, 2024 |
| DEFA14A | Additional proxy material | Jul 21, 2023 | — |
| DEF 14A | Proxy statement | Jul 10, 2023 | Jul 10, 2023 |
| PRE 14A | Preliminary proxy statement | Jun 30, 2023 | Jun 30, 2023 |
| DEF 14A | Proxy statement | May 19, 2023 | May 19, 2023 |
| DEF 14A | Proxy statement | Jun 8, 2022 | Jun 8, 2022 |
| PRE 14A | Preliminary proxy statement | May 26, 2022 | May 26, 2022 |
| DEFA14A | Additional proxy material | May 21, 2021 | — |
| DEF 14A | Proxy statement | May 21, 2021 | May 21, 2021 |
| PRE 14A | Preliminary proxy statement | May 10, 2021 | May 10, 2021 |
| DEFA14A | Additional proxy material | May 26, 2020 | — |
| DEF 14A | Proxy statement | May 26, 2020 | May 26, 2020 |
| PRE 14A | Preliminary proxy statement | Apr 28, 2020 | Apr 28, 2020 |
| DEFA14A | Additional proxy material | Jun 26, 2019 | — |
| DEFA14A | Additional proxy material | Jun 18, 2019 | — |
| DEF 14A | Proxy statement | Jun 18, 2019 | Jun 18, 2019 |
| PRE 14A | Preliminary proxy statement | Jun 7, 2019 | Jun 6, 2019 |
| DEFA14A | Additional proxy material | Jul 30, 2018 | — |
| DEF 14A | Proxy statement | Jul 30, 2018 | Jul 27, 2018 |
| PRE 14A | Preliminary proxy statement | Jul 2, 2018 | Jul 2, 2018 |
| PRE 14C | Filing | May 7, 2018 | May 7, 2018 |
| DEFA14A | Additional proxy material | May 3, 2017 | — |
| DEF 14A | Proxy statement | Apr 28, 2017 | Apr 28, 2017 |
| DEF 14C | Information statement | Sep 22, 2016 | Sep 22, 2016 |
| PRE 14C | Oncocyte corporation pre 14c 9-9-2016 | Sep 12, 2016 | Sep 9, 2016 |
| DEFA14A | Additional proxy material | May 5, 2016 | — |
| DEF 14A | Proxy statement | Apr 29, 2016 | Jun 9, 2016 |
Showing 32 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- IMDX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- CA
- Headquarters
- Nashville, TN
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1642380
- Former names
- OncoCyte Corp (until Jun 17, 2025); Oncocyte Corp (until Jun 17, 2025)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Myriad Genetics Inc MYGN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.